TY - JOUR
T1 - Recent advances in the treatment of acute lymphoblastic leukemia
AU - Rafei, Hind
AU - Kantarjian, Hagop M.
AU - Jabbour, Elias J.
N1 - Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2019/9/19
Y1 - 2019/9/19
N2 - Acute lymphoblastic leukemia (ALL) is a heterogeneous disease with a bimodal distribution. The progresses made in understanding its biology led to the development of targeted therapies. In this review, we summarize the current and future approaches in management of adult ALL. Tyrosine kinase inhibitors (TKI) targeting BCR-ABL1 tyrosine kinase, monoclonal antibodies targeting cell surface antigens (CD19, CD20, and CD22), bispecific antibodies, and chimeric antigen receptor (CAR)-T therapy are breakthrough treatments. They resulted in FDA approvals of blinatumomab in 2014, inotuzumab ozagamicin in 2017, and tisagenlecleucel in 2017 for relapsed/refractory ALL. Currently, long-term survival is achieved in more than 50% of patients with precursor B-ALL (50–70% in patients with Philadelphia chromosome (Ph)-positive ALL), 50–60% T-ALL, and 80% mature B-ALL. Ongoing efforts exist to optimize therapeutic options in both the relapsed/refractory as well as the frontline settings. In the era of precision medicine, the future lies in using less cytotoxic and more targeted agents.
AB - Acute lymphoblastic leukemia (ALL) is a heterogeneous disease with a bimodal distribution. The progresses made in understanding its biology led to the development of targeted therapies. In this review, we summarize the current and future approaches in management of adult ALL. Tyrosine kinase inhibitors (TKI) targeting BCR-ABL1 tyrosine kinase, monoclonal antibodies targeting cell surface antigens (CD19, CD20, and CD22), bispecific antibodies, and chimeric antigen receptor (CAR)-T therapy are breakthrough treatments. They resulted in FDA approvals of blinatumomab in 2014, inotuzumab ozagamicin in 2017, and tisagenlecleucel in 2017 for relapsed/refractory ALL. Currently, long-term survival is achieved in more than 50% of patients with precursor B-ALL (50–70% in patients with Philadelphia chromosome (Ph)-positive ALL), 50–60% T-ALL, and 80% mature B-ALL. Ongoing efforts exist to optimize therapeutic options in both the relapsed/refractory as well as the frontline settings. In the era of precision medicine, the future lies in using less cytotoxic and more targeted agents.
KW - Clinical results
KW - antibody-based immunotherapy
KW - lymphoid leukemia
UR - http://www.scopus.com/inward/record.url?scp=85074551956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074551956&partnerID=8YFLogxK
U2 - 10.1080/10428194.2019.1605071
DO - 10.1080/10428194.2019.1605071
M3 - Review article
C2 - 31092071
AN - SCOPUS:85074551956
SN - 1042-8194
VL - 60
SP - 2606
EP - 2621
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 11
ER -